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Levels of the p53 tumor suppressor protein are increased in human cytomegalovirus (HCMV)-infected cells
and may be important for HCMV pathogenesis. In normal cells p53 levels are kept low due to an autoregulatory
feedback loop where p53 activates the transcription of mdm2 and mdm2 binds and ubiquitinates p53, targeting
p53 for proteasomal degradation. Here we report that, in contrast to uninfected cells, mdm2 was undetectable
upon treatment of infected fibroblasts with the proteasome inhibitor MG132. Cellular depletion of mdm2 was
reproducible in p53-null cells transfected with the HCMV IE2-86 protein, but not with IE172, independently
of the endogenous mdm2 promoter. IE2-86 also prevented the emergence of presumably ubiquitinated species
of p53. The regions of IE2-86 important for mdm2 depletion were those containing the sequences correspond-
ing to the putative zinc finger and C-terminal acidic motifs. mdm2 and IE2-86 coimmunoprecipitated in
transfected and infected cell lysates and in a cell-free system. IE2-86 blocked mdm2’s p53-independent
transactivation of the cyclin A promoter in transient-transfection experiments. Pulse-chase experiments re-
vealed that IE2-86 but not IE1-72 or several loss-of-function IE2-86 mutants increased the half-life of p53 and
reduced the half-life of mdm2. Short interfering RNA-mediated depletion of IE2-86 restored the ability of
HCMV-infected cells to accumulate mdm2 in response to proteasome inhibition. Taken together, the data
suggest that specific interactions between IE2-86 and mdm2 cause proteasome-independent degradation of
mdm2 and that this may be important for the accumulation of p53 in HCMV-infected cells.
Human cytomegalovirus (HCMV) is a betaherpesvirus that
infects the majority of the population and is best known for
causing birth defects and health problems in immunocompro-
mised individuals such as transplant recipients and AIDS pa-
tients (8). Seropositivity for HCMV also correlates with
poorer clinical outcomes for inflammatory bowel diseases,
allograft rejection, atherosclerosis, and coronary restenosis
following angioplasty. There are a number of reports of
increased p53 and phosphorylated p53 in HCMV-infected
cells and cells expressing the HCMV immediate-early (IE)
protein IE2-86 (32, 51, 58, 60). However, the detailed mech-
anism of such an increase and its biological significance are
not well understood.
The effects of HCMV on coronary smooth muscle cells were
correlated with p53 accumulation and IE2-86-mediated inhi-
bition of p53 functioning (60). This was evidenced by reports
that IE2-86 expression in HCMV-infected cells mirrored p53
induction and IE2-86 coimmunoprecipitated p53 (59). IE2-86
also blocked reporter gene activity from p53-responsive pro-
moters without interfering with p53 binding to its target DNA
sequences (61). Steady-state levels of p21, a cyclin-dependent
kinase inhibitor whose levels are indicative of p53 transcrip-
tional activity, are decreased in HCMV-infected cells (12, 23,
52). However, either IE1-72 or IE2-86 alone increased the
relative amounts of p21 in transfected cells (10, 58).
p53 is a cellular tumor suppressor protein that is induced in
response to a variety of stresses, including cellular DNA dam-
age, and is critical in arresting cell growth and the induction of
apoptosis (41). Levels of p53 are normally maintained in a
regulatory circuit with mdm2. p53 induces the transcription of
mdm2, a ubiquitin ligase that targets p53 for proteasomal deg-
radation (49). A variety of posttranslational modifications to
p53, such as serine 15 phosphorylation by ataxia telangiectasia-
mutated and Rad 3-related kinases, are capable of breaking
the p53-mdm2 regulatory loop and increasing levels of p53 (3).
HCMV IE proteins are promiscuous transactivators with
multiple functions (11). They block apoptosis (71) and are
capable of stimulating quiescent cells into G1/S phase (70) and
arresting cell cycle progression at the same border (43). IE1-72
and IE2-86 bind and phosphorylate retinoblastoma (Rb) fam-
ily members, resulting in the upregulation of cyclin E/cdk2
kinase activity and E2F/DP transcription factor release (47, 54,
64, 68), respectively. Cells transfected with IE2-86 show pre-
dominant activation of E2F-responsive genes (57), while
IE1-72 causes the release of cyclin E/cdk2 from its inactive
complex (68). IE1-72 is a serine/threonine protein kinase (53)
that appears to be dispensable for HCMV replication under
high multiplicities of infection (29), while IE2-86 is not (46).
Either IE1-72 or IE2-86 can induce p53 (51), but IE2-86 is
considered the dominant factor that induces and inactivates
p53 during HCMV infection for the reasons described above.
Productive infection for a number of DNA viruses is accom-
panied by increased levels of inactive p53 (15). While it re-
mains unclear how these viruses induce p53, it is likely that
upregulation of p53, particularly as an effector of apoptosis, is
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not conducive to viral replication. Numerous DNA viruses
encode proteins that undermine p53 functioning. The best
known of these include the adenovirus E1 proteins, human
papillomavirus E6 and E7, and the large T antigen of poly-
omaviruses (41).
While a great deal of attention has been paid to the effects
of virus infection upon p53, relatively little work has been done
to characterize mdm2 in virus-infected cells. Knockout exper-
iments suggest that mdm2 is at least as biologically important
as p53. p53-negative mice display mild phenotypes and are
susceptible to spontaneous tumors (19). Mdm2 knockouts are
embryonic lethal and can be rescued by codeletion of p53 (36,
50). While mdm2 levels can indicate p53 transcriptional activ-
ity, mdm2 is its own ubiquitin ligase and a number of p53-
independent functions have been described for mdm2, such as
cell cycle regulation, differentiation, and transcriptional trans-
activation (25).
IE2-86, p53, and mdm2 are all known to bind and/or affect
a variety of proteins associated with transcriptional activation
and cell cycle regulation. For example, both IE2-86 and mdm2
bind to p53, Rb, TATA box-binding protein, Sp1, and p300/
CBP (11, 25). Mdm2 links the Rb and p53 tumor suppressor
pathways as a trimeric complex of Rb-mdm2-p53 (31). Many
biologically relevant aspects of the interactions among these
proteins and their corresponding pathways remain unresolved.
There is peripheral evidence to suggest that mdm2 may be
either upregulated or downregulated in HCMV-infected cells.
HCMV infection proceeds with the phosphorylation of Akt,
Rb, and mitogen-activated protein kinases ERK1 and -2 (32–
34, 55). Each of these events has induced mdm2 in other
systems. Inhibition of mdm2 resulted in p21 induction inde-
pendently of p53 (69), yet p21 is downregulated in HCMV-
infected cells (12, 52). These observations suggest that mdm2
might be upregulated in response to HCMV infection. How-
ever, the increase in p53 levels and the lack of p53 transcrip-
tional activity in HCMV-infected cells (60, 61) suggest that
mdm2 might be downregulated in HCMV infection. Also, Sp1
transcription factors are induced in HCMV-infected cells (67)
and mdm2 has been shown to inhibit Sp1-mediated transcrip-
tion (35).
We are aware of only one report that has examined the
status of mdm2 during HCMV infection. In situ hybridization
and immunohistochemistry of human tissue sections correlated
p53 induction with HCMV infection, yet infected cells dem-
onstrated mutually exclusive patterns of either p21 or mdm2
induction (26). This study was initiated as an inquiry into the
mechanism of p53 accumulation in HCMV-infected fibroblasts
and to examine the fate of mdm2 in cells productively infected
with HCMV and its implications for the effects of this virus
upon the p53-mdm2 regulatory loop.
MATERIALS AND METHODS
Reagents. MG132 was purchased from Sigma (St. Louis, MO). Antibodies to
p53 (DO-1 and FL-393) and mdm2 (SMP-14) were purchased from Santa Cruz
(Santa Cruz, CA). Antibodies to HCMV IE1-72 and IE2-86 proteins were
prepared as described previously (39). Antibody to -actin (CP01) was from
Oncogene (San Diego, CA). Protein G-Sepharose and glutathione-Sepharose 4B
were from Amersham Biosciences (Piscataway, NJ). All other reagents were
from Sigma and were of at least reagent grade.
Plasmids. pCMV-HDM2 and pcDNA3-myc3-HDM2 were gifts from Yue
Xiong. (Elsewhere in this publication we employ the term mdm2 regardless of
the organism of origin.) The reporter plasmid expressing firefly luciferase
from the cyclin A promoter (WT-Luc) was prepared as described previously
(14). Control plasmid expressing Renilla luciferase from a herpes simplex
virus thymidine kinase promoter (pRL-TK) was purchased from Promega
(Madison, WI).
pcDNA3IE2 containing IE2-86 cDNA was used as a template for PCR to
produce full-length protein and the following deletions: IE2-26-579, encoding
amino acids (aa) 26 to 579; IE2-D325-448, encoding aa 1 to 324 and 449 to 579;
IE2-1-324, encoding aa 1 to 324; and IE2-1-538, encoding aa 1 to 538. A C-
terminal Flag tag was incorporated into the primer design of each construct. The









Each PCR fragment contained a BamHI restriction site at the 5 terminus and
a 3-terminal EcoRI restriction site. These restriction sites were used to insert
PCR fragments into the multiple cloning sequence of the pcDNA3 expression
vector to construct Flag-tagged pcDNA3IE2f, pcDNA3IE2-26-579f, pcDNA3IE2-
D325-448f, pcDNA3IE2-1-324f, and pcDNA3IE2-1-538f. Ligation of the same
fragments into plasmid pGEX-2T resulted in N-terminal glutathione S-trans-
ferase (GST) expression vectors pGEX-2TIE2f, pGEX-2TIE2-26-579f, pGEX-
2TIE2-D325-448f, pGEX-2TIE2-1-324f, and pGEX-2TIE2-1-538f.
Cell culture. Human embryonic lung fibroblasts (HEL 299), BHK-21, and
p53-null H1299 cells were obtained from the American Type Culture Collection
(Manassas, VA). Cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) with 5 to 10% fetal bovine serum, 100 U/ml penicillin, and 100 g/ml
streptomycin at 37°C in an atmosphere of 6% CO2. Cells were infected with
HCMV Towne strain (passages 36 to 42) that had been purified through a
sucrose cushion to eliminate cytokines and growth factor contamination at a
multiplicity of infection (MOI) of 2 to 5 PFU/cell.
Western blot assays. Following treatments and incubation periods in 100-mm
dishes, cell monolayers were harvested by washing in phosphate-buffered saline
(PBS) and scraping in 2 sodium dodecyl sulfate (SDS) loading buffer. Samples
were boiled and proteins were separated by SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE) and then transferred to Immobilon-P membranes (Mil-
lipore; Bedford, MA). Membranes were blocked for 30 min in 5% (wt/vol) nonfat
dry milk in PBS with 0.1% Tween 20 (PBS-T). Blots were probed with primary
antibodies overnight at 4°C. Membranes were washed with PBS-T, probed with
secondary horseradish peroxidase-conjugated antibodies, and then washed and
developed by enhanced chemiluminescence (ECL) according to the manufac-
turer’s instructions (Amersham).
p53 ubiquitination assay. HEL cells incubated in DMEM without serum for
48 h were infected with HCMV at an MOI of 2 to 5 PFU/cell. Fourteen hours
postinfection, MG132 was added to cells to a final concentration of 30 M. Cells
were harvested following 10 hours treatment with MG132, corresponding to 24 h
postinfection.
Immunoprecipitation for p53 ubiquitination. The p53-null H1299 cells were
transfected with vectors encoding mdm2, p53, IE1-72, IE2-86, and IE2-86 dele-
tions in the combinations indicated in the figure legends using Effectene (QIA-
GEN, Valencia, CA) according to the manufacturer’s instructions. Sixty-two
hours posttransfection, the proteasome inhibitor MG132 was added to a final
concentration of 30 M and presumably ubiquitinated species were allowed to
accumulate for approximately 10 h. Cells were harvested by scraping in ice-cold
PBS and pelleted and then lysed in denaturing buffer containing 50 mM Tris-
HCl, 0.5 mM EDTA, 1% SDS, and 1 mM dithiothreitol, followed directly by
boiling for 10 min to avoid coimmunoprecipitation of another ubiquitinated
protein(s). Lysates were diluted 10-fold in EBC (0.05 M Tris-HCl, pH 8.0, 0.12
M NaCl, 0.5% NP-40, 0.1 M NaF, 0.2 mM sodium orthovanadate, 1 mM phen-
ylmethylsulfonyl fluoride, 10 g/ml leupeptin, and 10 g/ml aprotinin) buffer,
followed by immunoprecipitation with anti-p53 (FL-393).
Protein-protein interaction detection. Cells were harvested by scraping in
ice-cold PBS and pelleted and then lysed in EBC. Cell extracts of 500 g of
protein were first precleared with protein G-Sepharose beads for 1 h at 4°C and
extracts were incubated with the appropriate antibody for 4 h. Protein complexes
were precipitated by incubation with protein G-Sepharose beads overnight at
4°C. Precipitated complexes were washed four times with 1 ml of ELB buffer
(0.25 M NaCl, 0.1% NP-40, 0.05 M HEPES, pH 7.0, 1 mM phenylmethylsulfonyl
fluoride, 5 mM EDTA, and 0.5 mM dithiothreitol) and then resuspended in 2
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sample buffer and boiled for 8 min. Proteins were separated by SDS-PAGE and
analyzed by Western blotting.
Protein interaction. Transcription-translation of mdm2 was performed with a
TnT-coupled reticulocyte lysate system (Promega) for 35S labeling using
pcDNA3-myc3-HDM2 as the template DNA. Equal amounts of the resulting
protein were mixed individually with 25 l of a complex of glutathione, Sepha-
rose 4B, GST, and IE2-86 (described below) and its deletions at 4°C overnight in
0.3 ml of ELB buffer. Beads were washed with ELB buffer four times prior to
boiling in 2 SDS-PAGE loading buffer and Western blotting and autoradiog-
raphy.
GST–IE2-86 and its deletions were expressed in Escherichia coli BL21 bacteria
and purified with glutathione-Sepharose 4B. Expression from pGEX-2T vectors
containing IE2-86 or its deletion cDNAs was induced in transformed BL21 cells
with 0.5 mM isopropylthiogalactopyranoside (IPTG) for 2 h. Bacteria were
centrifuged at 2,500  g for 10 min and pellets were resuspended in 1 ml cold
PBS with 0.1 mM phenylmethylsulfonyl fluoride for each 10 ml of original
culture. Suspensions were freeze-thawed three times, sonicated, and centrifuged
at 13,000  g for 15 min. Supernatants were mixed with 25 l glutathione-
Sepharose 4B beads for 4 h at 4°C on a rocking platform. Beads were washed
with 1 ml cold PBS with 0.1 mM phenylmethylsulfonyl fluoride four times. These
complexes of glutathione, Sepharose, GST, and IE2-86 or its deletions were used
for pulldown experiments.
Pulse-chase. H1299 cells were incubated to 80% confluence in 60-mm dishes
and were transfected with 2 g of each expression plasmid indicated in Fig. 6 to
8 and adjusted to a total of 6 g with pcDNA3 empty vector to standardize input
plasmid DNA. Twenty-four hours posttransfection, cells were pulse-labeled with
[35S]methionine Translabel (MB Biosciences, Irvine, CA) in medium lacking
methionine for 2 h, washed twice with PBS, and chased with fresh medium with
10% fetal bovine serum for the times indicated in Fig. 6 to 8.
The cells were scraped and washed twice with PBS and lysed in 300 l EBC
buffer at 4°C on ice for 1 h. Lysates were mixed with extra 300 l EBL buffer
and 25 l of protein G-Sepharose 4B for preclearance, and 0.5 g anti-p53 DO-1
or 0.5 g anti-mdm2 antibody was added. Samples were placed on a rocking
platform at 4°C for 1 h, and 25 l protein G-Sepharose beads was added, and
samples were gently mixed at 4°C for 3 h. Immunoprecipitation complexes were
run out by SDS-PAGE and gels were dried and autoradiographed. The resulting
films were analyzed with New ImageQuant TL v2003.01.
Reporter gene assays. BHK-21 cells were transfected with various combina-
tions of plasmids as indicated using Effectene. Cells were grown in six-well plates
and transfected when a density of 90% confluence was reached. A total of 1.0 g
of DNA was used in each transfection. The mixture of vectors and Effectene
reagent was added to the cells in 1.5 ml of DMEM without serum. Cells were
incubated at 37°C and 6% CO2 for an additional 18 h prior to dual luciferase
assays that were performed according to the manufacturer’s instructions (E1910;
Promega). Firefly and Renilla luciferase activities were quantified on an LB 9501
luminometer (Berthold Technologies; Bad Wildbad, Germany) and raw data
were normalized to the Renilla luciferase activities, which served as internal
controls.
IE2-86 knockdown by siRNA. The short interfering RNA (siRNA) oligonu-
cleotide 5-AAACGCAUCUCCGAGUUGGACdTdT-3 and the complement
5-GUCCAACUCGGAGAUGCGUUUdTdT-3 targeting HCMV IE2-86 were
synthesized by Dharmacon (Lafayette, CO) as described previously (65). We
employed siRNA-Cy3 (QIAGEN) (sense sequence, UUCUCCGAACGUGU
CACGUdTdT; 3-Cy3) as a nonspecific control. HEL cells were grown to con-
fluence in 100-mm dishes at 37°C in an atmosphere of 6% CO2 and serum
starved for 24 h. Dishes of cells were transfected with 10 l Lipofectamine 2000
and 5 l 20 M siRNA according to the manufacturer’s instructions (Invitrogen).
Four hours later cells were washed twice with DMEM and the medium was
replaced with DMEM. Twenty-four hours posttransfection cells were infected
with 2 to 5 PFU/cell HCMV. Six hours postinfection MG132 was added to the
cell culture medium to a final concentration of 30 M, and plates were incubated
an additional 10 h prior to harvesting for Western blot assays.
RESULTS
Status of mdm2 and p53 in HCMV-infected cells. We were
unable to measure endogenous mdm2 levels in HEL fibroblasts
by Western blotting (Fig. 1, lane 1 of upper panel), presumably
due to the low levels and/or high turnover rates described else-
where for this protein (24, 37). Mdm2 remained undetectable
upon infection with HCMV (Fig. 1, lane 2 of upper panel). In
HCMV-infected cells treated with the proteasome inhibitor
MG132, p53 and IE2-86 levels were higher than in HCMV-in-
fected cells without MG132 (Fig. 1, lanes 2 and 4 of upper panel).
Mdm2 was detectable by Western blotting when uninfected cells
were treated with MG132, yet mdm2 remained undetectable
when HCMV-infected cells were treated with MG132 (Fig. 1,
lanes 3 and 4 of upper panel).
Since mdm2 is known to function as a ubiquitin ligase and
facilitate p53 ubiquitination and degradation (49), we exam-
ined the same system for ubiquitinated species of p53 by im-
munoprecipitation and Western blotting. Slowly migrating spe-
cies of p53 consistent with ubiquitin conjugation were detected
in uninfected cells treated with MG132 but little accumulated
in the corresponding HCMV-infected cells (Fig. 1, lanes 3 and
4 of bottom panel).
HCMV IE2-86 reduced both mdm2 levels and p53 ubiquiti-
nation. Previous reports have established (51) and we have
reproduced the observation (data not shown) that p53 accu-
mulation is detectable from 4 h post-HCMV infection of fi-
broblasts. This prompted examination of the effects of IE1-72
and IE2-86 upon p53 ubiquitination. Mammalian expression
vectors encoding these immediate-early gene products, mdm2,
and p53 from CMV promoters were transfected into H1299
(p53-null) cells. Slower-migrating species of p53 suggesting
ubiquitination were reduced in cells transfected with IE2-86,
mdm2, and p53 (Fig. 2, lane 2 of bottom panel), but not in cells
transfected with IE1-72, mdm2, and p53 (Fig. 2, lane 3 of
bottom panel). mdm2 levels were reduced in cells transfected
with IE2-86, mdm2, and p53 compared to those in cells trans-
fected with mdm2 and p53 in the presence or absence of
IE1-72 (Fig. 2, compare lane 2 to lanes 1 and 3 in upper panel).
This suggested that IE2-86 expression, but not IE1-72, results
FIG. 1. Effects of HCMV infection upon mdm2 and ubiquitinated
p53 as measured by immunoblotting. HEL fibroblasts were infected
with HCMV and harvested at 24 h postinfection with or without a 10-h
treatment with the proteasome inhibitor MG132 (30 M). The upper
panel represents direct loading and immunoblotting with the antibod-
ies indicated, while the data in the bottom panel were obtained from
immunoprecipitation and Western blotting. IP, immunoprecipitation;
W, Western blotting; Ub, ubiquitin; IgG, immunoglobulin G.
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in the inhibition of p53 ubiquitination and the depletion of
mdm2, independently of their endogenous promoters.
Regions of IE2-86 governing mdm2 depletion and p53 ubiq-
uitination. To examine the domains of IE2-86 that downregu-
lated mdm2, full-length and four deletion mutants of IE2-86
(pcDNA3IE2-26-579f, pcDNA3IE2-D325-448f, pcDNA3IE2-
1-324f, and pcDNA3IE2-1-538f) were transfected into H1299
cells with mdm2 and p53 as indicated in Fig. 3. The expression
of Flag-tagged full-length and deletion IE2-86 proteins was
confirmed by Western blotting (Fig. 3a). Full-length IE2-86
and the mutant lacking amino acids 1 to 25 (IE2-26-579f)
reduced the levels of mdm2 and stabilized those of p53 (Fig.
3a, lanes 3 and 4), yet the other three (IE2-D325-448f, IE2-1-
538f, and IE2-1-324f) mutants did not (Fig. 3a, lanes 5, 6, and
7). When we immunoprecipitated p53, cells transfected with
full-length IE2-86 and IE2-26-579f did not display slowly mi-
grating species of p53 that would be consistent with ubiquiti-
nation (Fig. 3b, lanes 3 and 4). Similarly, little mdm2 was
detected in complex with p53 upon transfection with IE2-86 or
IE2-26-579f (Fig. 3b, lanes 3 and 4).
Immunoprecipitation of IE2-86 and its deletion mutants by
their Flag epitopes allowed for the identification of interacting
proteins. The mutant IE2-86 lacking amino acids 325 to 448
(IE2-D325-448f) was the most efficient at pulling down p53
despite slightly lower levels of p53 in this sample (Fig. 3c and
a, lanes 5). Full-length IE2-86 and those mutants lacking
amino acids 1 to 25 (IE2-26-579f), 325 to 448 (IE2-D325-448f),
or 539 to 579 (IE2-1-538f) coimmunoprecipitated p53 (Fig. 3c,
lanes 3, 4, 5, and 6), yet the 325 to 579 deletion mutant (IE2-
1-324f) did not (Fig. 3c, lane 7). Full-length IE2-86, IE2-26-
579f, and IE2-1-538f coimmunoprecipitated mdm2 (Fig. 3d,
lanes 3, 4, and 6), yet mutants IE2-D325-448f and IE2-1-324f
did not (Fig. 3d, lanes 5 and 7). This was observed despite the
lower levels of mdm2 in cells transfected with full-length
IE2-86 and IE2-26-579f (Fig. 3a, lanes 3 and 4). We observed
a similar pattern when we immunoprecipitated mdm2 with
anti-p53 (FL393) antibody (Fig. 3b, lanes 3 and 4). mdm2
efficiently pulled down full-length IE2-86, IE2-26-579f, and
IE2-1-538f (lanes 3, 4, and 6 in Fig. 3e) but not IE2-D325-448f
or IE2-1-324f (Fig. 3e, lanes 5 and 7). However, mdm2 coim-
munoprecipitated p53 regardless of the presence or absence of
IE2-86 and its mutants (Fig. 3f).
Taken together, the data suggested that the putative zinc
finger (amino acids 428 to 452) and/or acidic (amino acids 551
to 579) domain of IE2-86 (45) may be necessary for mdm2
FIG. 2. Effects of IE2-86 upon mdm2 and ubiquitinated p53.
H1299 (p53-null) cells were transfected with expression vectors encod-
ing mdm2, IE1-72, IE2-86, and p53. Lysates of H1299 cells transfected
with the indicated expression victors were analyzed by immunoblotting
(upper panel) or by immunoprecipitation followed by Western blotting
(bottom panel). IP, immunoprecipitation; W, Western blotting; Ub,
ubiquitin; IgG, immunoglobulin G.
FIG. 3. Mapping the regions of IE2-86 responsible for mdm2 de-
pletion, inhibition of p53 ubiquitination, and protein interactions.
H1299 (p53-null) cells were transfected with expression vectors encod-
ing mdm2, p53, IE2-86, and IE2-86 deletion mutants. (a) Whole-cell
lysates were directly analyzed by Western blotting. (b) p53 was immu-
noprecipitated from lysates by anti-p53 (FL-393) antibody to deter-
mine mdm2 binding or p53 species. (c and d) IE2-86 and mutants were
immunoprecipitated by their Flag epitopes and samples were exam-
ined for p53 and mdm2 complexes. (e and f) mdm2 was immunopre-
cipitated and complexes were examined for IE2-86 and its mutants as
well as p53. IP, immunoprecipitation; W, Western blotting; Ub, ubiq-
uitin; IgG, immunoglobulin G.
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reduction and the inhibition of p53 ubiquitination. Since IE2-
D325-448f efficiently pulled down p53 (Fig. 3c, lane 5) but
poorly bound mdm2 (Fig. 3d, lane 5), and IE2-1-538 efficiently
interacted with mdm2 (Fig. 3d and e, lanes 6) but did not
reduce mdm2 and inhibit p53 ubiquitination (Fig. 3a and b,
lanes 6), it appeared possible that the physical and functional
interactions between IE2-86 and mdm2 might be independent
of the described physical and functional associations between
IE2-86 and p53 (60, 61) and between p53 and mdm2 (41).
Direct interactions between IE2-86 and mdm2. To assess the
possibility that IE2-86 might interact directly with mdm2 in the
absence of p53 or other cellular factors, we employed cell-free
pulldown experiments. GST-tagged full-length and deletion
mutants of IE2-86 were expressed in E. coli BL21 and collected
on glutathione-Sepharose beads. These beads were incubated
with [35S]methionine-labeled mdm2 produced by in vitro tran-
scription-translation. Complexes retained on beads were exam-
ined by autoradiography for mdm2 (Fig. 4A, upper panel) and
by Coomassie blue staining to confirm the presence of IE2
species (Fig. 4A, bottom panel). These results suggested that
full-length IE2-86 and its mutants encoding amino acids 26 to
579 and 1 to 538 specifically interacted with mdm2 (Fig. 4A,
lanes 1, 2, and 3 of upper panel) and were consistent with the
HCMV-infected cell experiments shown in Fig. 3.
To investigate whether or not the specific interaction be-
tween IE2-86 and mdm2 could be reproduced in the context of
an actual virus infection, cells were pretreated with 20 to 30
M MG132 for 10 h and then infected with HCMV for the
analysis of mdm2-IE2-86 complexes by immunoprecipitation
followed by Western blotting. We found that cells pretreated
with MG132 poorly expressed IE2-86 upon infection (Fig. 4B,
lanes 3 and 4 of upper panel). This was consistent with reports
that pretreatment of cells with MG132 blocked HCMV acti-
vation of NF-B and virus infectivity (16, 17). In order to
provide a system where MG132-treated cells and virus-infected
cells expressing IE2-86 could be examined together, we mixed
the lysates of HCMV-infected cells with MG132-treated cells
and subjected the mixture to immunoprecipitation followed by
Western blotting (Fig. 4B, lanes 5 and 6 of bottom panel).
These conditions reproduced the mdm2-IE2-86 complexes ob-
served by in vitro transcription-translation (Fig. 4A).
IE2-86 blocked mdm2’s transactivation of the cyclin A pro-
moter. In order to substantiate the possibility that IE2-86’s
downregulation of mdm2 was independent of p53, we em-
ployed a reporter gene assay using firefly luciferase expression
from a cyclin A promoter. mdm2 was shown to increase cyclin
A promoter activity independently of p53 (40). Figure 5 shows
that mdm2 increased cyclin A promoter activity approximately
sixfold in BHK-21 cells, similar to what was reported by others
(40). Cotransfection with IE2-86 blocked mdm2-dependent
transactivation in a dose-dependent manner but did not affect
basal levels of cyclin A promoter activity (Fig. 5, lanes 2, 3, 4,
FIG. 4. Direct interactions between IE2-86 and mdm2. (A) In vitro translation reveals direct interaction between IE2-86 and mdm2. GST-
tagged IE2-86 and its deletion mutants were expressed in bacteria (as verified by Western blotting; data not shown) and collected on glutathione-
Sepharose beads that were incubated with [35S]mdm2 produced by in vitro transcription-translation. Specifically bound mdm2 was determined by
autoradiography. Complexes formed by [35S]mdm2 and GST-IE2-86 or its deletion mutants were analyzed by SDS-PAGE and autoradiography
(upper panel) and expression of GST-IE2 and its deletion mutants in BL21 cells was determined by SDS-PAGE and Coomassie blue staining
(bottom panel). (B) Coimmunoprecipitation of IE2-86 and mdm2 from lysates of MG132-treated or HCMV-infected HEL cells. The upper panel
shows Western blots for mdm2 and IE2-86 in cell lysates. HEL cells were treated with 20 M MG132 for 10 h prior to and 8 h postinfection (lanes
2 and 3) or 30 M MG132 for 10 h (lane 5) after the time at which the cells in lanes 3, 4, and 6 were infected. The bottom panel shows
immunoprecipitation with anti-IE2 antibody and Western blots for mdm2 and IE2-86. Lanes 1 to 4 received the same treatments in the upper and
lower panels. In lane 56, the lysates of lanes 5 and 6 from the upper panel were mixed at 4°C for 1 h and the mixture was subjected to
immunoprecipitation with subsequent Western blotting. IP, immunoprecipitation; W, Western blotting; Ub, ubiquitin; IgG, immunoglobulin G.
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and 5). IE2-26-579f reversed mdm2 activation of the cyclin A
promoter (Fig. 5, lane 6), while mutants IE2-D325-448f and
IE2-1-538f did not reproducibly affect this system (Fig. 5, lanes
7 and 8). These results suggested that IE2-86 specifically
blocked mdm2-dependent, p53-independent transactivation of
the cyclin A promoter.
IE2-86 increased the half-life of p53 and reduced the half-
life of mdm2. Since IE2-86 decreased and increased the steady-
state protein levels of mdm2 and p53, respectively, indepen-
dently of their endogenous promoters, we examined the effects
of IE2-86 on the half-lives of mdm2 and p53. Pulse-chase
experiments were performed with p53-transfected [35S]methi-
onine-labeled H1299 cells cotransfected with combinations of
mdm2, IE1-72, and IE2-86 expression vectors as described in
the legend to Fig. 6. As expected, the half-life of p53 was
reduced when it was cotransfected with mdm2 (Fig. 6A, com-
pare a and b). When IE2-86 was cotransfected with p53 and
mdm2, the effects of mdm2 on p53 were fully reversed (Fig.
6A, compare b and c) and the levels of mdm2 protein were
reduced (Fig. 6B, compare b and c). In contrast, IE1-72 did not
change the effects of mdm2 on p53 (Fig. 6A and B, compare b
and d). These results suggested that IE2-86 stabilized p53 via
increasing its half-life independently of its effects upon the
endogenous p53 promoter and possibly by assisting the degra-
dation of mdm2.
We also performed pulse-chase experiments with mdm2-
transfected [35S]methionine-labeled H1299 cells cotransfected
with combinations of p53 and IE2-86 expression vectors. The
half-life of mdm2 was increased upon cotransfection with p53
(Fig. 7A and B, compare a and c) and decreased upon cotrans-
fection with IE2-86 (Fig. 7A and B, compare a and d). Co-
transfection with p53 and IE2-86 reduced the half-life of mdm2
(Fig. 7A and B, compare a and b) in a manner indistinguish-
able from cotransfection with IE2-86 alone (Fig. 7A and B,
compare a and d). Western blotting showed an increase in the
steady-state levels of p53 when it was cotransfected with mdm2
and IE2-86 compared to the level with mdm2 alone, which
correlated with decreased steady-state levels of mdm2 in the
presence of IE2-86 (Fig. 7A or C, compare a with b and d).
These experiments were repeated using IE2-86 deletion mu-
tants in order to correlate these experiments with the above
results. We found that the half-life of mdm2 was decreased in
cells cotransfected with full-length IE2-86 and IE2-86 lacking
amino acids 1 to 25 (IE2-26-579f) (Fig. 8A and B, b and c), but
not with any of the other corresponding deletion mutants em-
ployed (Fig. 8A and B, d, e, and f). These results suggested that
IE2-86 directly decreased the half-life of mdm2 independently
of p53 and that the putative zinc finger and/or acidic domain of
IE2-86 was required for this effect.
IE2-86 depletion in HCMV-infected cells restored mdm2
induction. In order to determine the contribution of IE2-86 to
mdm2 depletion in HCMV-infected cells, we intended to re-
produce the above phenomena using recombinant viruses with
IE2-86 deleted and/or mutated from infectious bacterial arti-
FIG. 5. Effects of HCMV IE2-86 upon mdm2-dependent transac-
tivation of the cyclin A promoter. BHK-21 cells were transfected with
a plasmid encoding firefly luciferase from a cyclin A promoter (WT-
Luc) and combinations of expression vectors encoding mdm2 and/or
IE2-86 and its mutants. Firefly luciferase activities were normalized to
the Renilla luciferase activities of an internal control plasmid (pRL-
TK) and relative firefly luciferase activities were determined by setting
WT-Luc transfections to 1.0 arbitrary unit. Values are presented as the
means  standard deviation of four independent experiments.
FIG. 6. Half-life of p53 is increased by IE2-86: pulse-chase. H1299
cells were transfected with expression vectors encoding p53 and the
indicated combinations of mdm2, IE1-72, and IE2-86 and pulsed with
[35S]Met and then chased with unlabeled amino acids for the indicated
times prior to harvesting. (A) Labeled p53 was detected by immuno-
precipitation followed by SDS-PAGE separation and autoradiography,
and then the resulting film was analyzed with New ImageQuant TL
v2003.01 for detecting relative levels of labeled p53 at the indicated
chase time points. (B) The amounts of p53, mdm2, IE2-86, and IE1-72
were determined by immunoblotting at the indicated chase time
points. “a” refers to transfection with p53, “b” refers to transfection
with p53 and mdm2, “c” refers to transfection with p53 and mdm2–
IE2-86, and “d” refers to transfection with p53 and mdm2 and IE1-72.
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ficial chromosome clones. However, IE2-86 knockouts have
been reported and they are replication incompetent (46).
Therefore we employed an siRNA knockdown strategy re-
ported previously (65) to significantly reduce IE2-86 expres-
sion in HCMV-infected cells. Treatment of HCMV-infected
cells with IE2-siRNA disrupted IE2-86 expression, but not that
of IE1-72 (Fig. 9, lanes 5 and 8). Specificity was also confirmed
using a negative control siRNA (Fig. 9, lanes 9 to 11). In the
context of HCMV infection, mdm2 levels accumulated upon
IE2-siRNA and MG132 treatment (Fig. 9, lane 8), but not
without MG132 or IE2-siRNA treatment (Fig. 9, lanes 5 and
6). The results suggested that only when the expression of
IE2-86 was blocked could HCMV-infected cells accumulate
measurable levels of mdm2 in response to MG132.
DISCUSSION
The aim of this study was to examine the status of mdm2 in
cells productively infected with HCMV and its implications for
the mechanism of p53 accumulation in virus-infected cells. The
steady-state levels of mdm2 and presumably ubiquitinated spe-
cies of p53 were decreased in response to HCMV infection in
a proteasome-independent manner (Fig. 1). These reductions
in mdm2 and ubiquitinated p53 were reproducible upon trans-
fection of cells with IE2-86 but not with IE1-72 (Fig. 2). IE1-72
and IE2-86 share the same 85 N-terminal amino acids and are
splice variants of the UL123 and 122 genes (11). Our exami-
nation of the regions of IE2-86 responsible for perturbation of
the mdm2-p53 autoregulatory loop suggested that the putative
zinc finger and C-terminal acidic domains were important for
mdm2 downregulation. IE2-86 amino acids 326 to 449 were
required for mdm2 binding and reducing the half-life of mdm2,
while amino acids 540 to 579 were required to reduce the
half-life of mdm2 but not for mdm2 binding.
The unique regions of IE1-72 and IE2-86 (exons 4 and 5,
respectively) have similar sequences that suggest zinc finger
motifs (amino acids 428 to 452), yet their orientations (H2C2
and C2H2, respectively) are opposite (27). The primary
amino acid sequence of IE2-86 also suggests the possibility of a
double zinc finger or Lin-11, Isl-1, and Mec-3 (LIM) domain from
residues 428 to 480 (CX5CX11HX5HX9DXCX13HXH) (Fig.
10A). LIM domains are multiple binding and adapter modules
containing specialized double zinc finger motifs that are impor-
tant for protein-protein interactions (5). These are responsible
for key interactions with coactivators, corepressors, competi-
tors, and other transcription factors and are therefore of con-
FIG. 7. Half-life of mdm2 is decreased by IE2-86: pulse-chase. H1299 cells were transfected with expression vectors encoding mdm2 and the
indicated combinations of p53 and IE2-86 and pulsed with [35S]Met and then chased with unlabeled amino acids for the indicated times prior to
harvesting. (A) Labeled mdm2 was detected by immunoprecipitation followed by autoradiography and the levels of other proteins were determined
by immunoblotting. (B) The autoradiographed film was analyzed with New ImageQuant TL v2003.01 to detect relative levels of labeled mdm2 at
the indicated chase time points. (C) The amounts of p53, mdm2, and IE2-86 were determined by immunoblotting at the indicated chase time
points. “a” refers to transfection with mdm2, “b” refers to transfection with mdm2 and p53 and IE2-86, “c” refers to transfection with mdm2 and
p53, and “d” refers to transfection with mdm2 and IE2-86. IP, immunoprecipitation; W, Western blotting; Ub, ubiquitin; IgG, immunoglobulin G.
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siderable importance for the regulation of associated transcrip-
tional activity.
It is possible that the zinc finger/LIM domain of IE2-86 may
mediate not only binding to mdm2, but also other protein-
protein interactions potentially facilitating mdm2 degradation,
such as interacting with the RING-H2 zinc finger protein
RLIM (5). It was reported that the putative IE2-86 zinc finger
(from C428 to H452) had no effect upon DNA binding, but
H446L and H452L IE2-86 mutants were unable to bind
DNA (4). It is possible that these mutations disrupted the
putative LIM domain.
Also important for IE2-86 downregulation of mdm2 was the
C-terminal acidic domain. The last 37 amino acids of IE2-86
have been shown to contain a transferable transactivation do-
main that is required for transactivation, autoregulation, and
DNA binding (4, 13, 30). The acidic domains of other proteins
were important for ubiquitination reactions (6, 42), suggesting
the possibility of a role for this region of IE2-86 in catalysis. An
IE2-86-mdm2 complex might recruit another coactivator(s),
corepressor(s), kinase(s), or component(s) responsible for pro-
tein degradation by synergy of its zinc finger/LIM and acidic
domains. While the specific function(s) of the identified IE2-86
domains remains speculative, the data indicated that both the
zinc finger/LIM and acidic domains of IE2-86 were required to
bring about mdm2 degradation. IE2-86 mutants IE2-D325-448
(zinc finger/LIM domain damage), IE2-1-324 (both zinc fin-
FIG. 8. The half-life of mdm2 is decreased only by full-length and IE2-26-579: pulse-chase. H1299 cells were transfected with expression vectors
encoding mdm2 and IE2-86 and its deletion mutants. Cells were pulsed with [35S]Met and chased with unlabeled amino acids for the indicated times prior
to harvesting. (A) Labeled mdm2 was detected by immunoprecipitation followed by autoradiography and the levels of other proteins were determined
by immunoblotting. (B) The autoradiographic film was analyzed with New ImageQuant TL v2003.01 to detect relative amounts of labeled mdm2 at the
indicated chase time points. (C) The amounts of p53, mdm2, and IE2-86 and its mutants were determined by immunoblotting at the indicated chase time
points. “a” refers to transfection with mdm2, “b” refers to transfection with mdm2 and IE2-86, “c” refers to transfection with mdm2 and IE2-26-579, “d”
refers to transfection with mdm2 and IE2-1-324, “e” refers to transfection with mdm2 and IE2-D325-448, and “f” refers to transfection with mdm2 and
IE2-1-538. IP, immunoprecipitation; W, Western blotting; Ub, ubiquitin; IgG, immunoglobulin G.
FIG. 9. Effect of siRNA directed to IE2-86 upon HCMV induction
of mdm2 as measured by immunoblotting. HEL fibroblasts were trans-
fected with siRNA to IE2-86 or a nonspecific control siRNA and then
infected with HCMV and treated with the proteasome inhibitor
MG132 (30 M) for 10 h prior to harvesting. Control -actin levels
indicate that similar levels of protein were loaded in each lane.
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ger/LIM and acidic region removal), and IE2-1-538 (acidic
domain removal) were unable to cause mdm2 degradation
(Fig. 3, 5, and 8).
Given that IE2-86 and mdm2 were known to bind at least
five proteins in common (see introduction), it seemed reason-
able to expect that these two proteins would be capable of
coimmunoprecipitation. As shown in Fig. 3 and 4B, this pre-
diction was validated. Pulldown experiments with in vitro-
translated protein were employed to examine the binding
properties of the isolated proteins. It was much more surpris-
ing that IE2-86 and mdm2 were capable of interactions in the
absence of other cellular proteins (Fig. 4A). The inabilities of
mutants GST–IE2-D325-448 and GST–IE2-1-324 to pull down
mdm2 suggested that the binding was specific (Fig. 4A).
We examined five events that occurred in the p53-mdm2
regulatory loop in response to full-length and deletion mutants
of IE2-86 (Fig. 10B). The IE2-D325-448 mutant bound p53 but
not mdm2, suggesting distinct binding interactions for IE2-86–
p53 and IE2-86–mdm2. Binding of IE2-86 to mdm2 was insuf-
ficient to block functional transactivation of the cyclin A pro-
moter by mdm2 or to prevent p53 ubiquitination. The mutants
of IE2-86 that were capable of binding mdm2 and down-
regulating its functions were the same as those that reduced
the half-life of mdm2. This suggested that IE2-86-mediated
functional downregulation of mdm2 resulted from mdm2
degradation.
The ability of IE2-86 to cause mdm2 depletion independent
of mdm2’s endogenous promoter suggested that regulation
was not at the transcriptional level. It is not clear how IE2-86
facilitated mdm2 degradation. The inability to recover mdm2
in the presence of MG132 suggested that this phenomenon was
proteasome independent. Since the binding of IE2-86 to mdm2
was not sufficient to degrade mdm2, it is possible that other
functions of IE2-86 are required for mdm2 degradation. Pos-
sible functions include those that might mediate subcellular
localization, catalysis, conformational changes, or the recruit-
ment of another protein(s) that might degrade mdm2.
Since p53 transcriptional activity controls mdm2 expression
and IE2-86 likely blocks p53 transcriptional activity, it seems
unnecessary for HCMV to employ IE2-86 to facilitate mdm2
degradation. An apparent duplication of functions is also em-
ployed by HCMV to block cellular apoptosis. At least five
cytomegalovirus proteins (vMIA, vICA, m41, IE1-72, and IE2-
86) are independently capable of blocking apoptosis (9, 28, 56,
66, 71). vICA is dispensable for viral growth in cell culture (56)
and IE1-72 is not required for efficient HCMV replication at
high multiplicities of infection (29). This is consistent with the
proposal that degenerate or multiple viral solutions to host
countermeasures may be important virulence factors in vivo
(2) and are not unique to mdm2. An alternative explanation is
that p53 transcriptional activity may not be absent in HCMV-
infected cells. Transfection of fibroblasts with IE2-86 did not
prevent the induction of p53, mdm2, and p21 by actinomycin
D, nor did it block cell cycle arrest (7, 44).
Another interesting question is how mdm2 depletion might
facilitate HCMV replication. If the p53 induced by HCMV
infection is not functional, then at issue are the p53-indepen-
dent effects of mdm2. Several speculative explanations follow.
HCMV IE1-72 and IE2-86 bring about the disruption of pro-
myelocytic leukemia (PML) associated nuclear bodies (ND10
or PML oncogenic domains) causing diffuse nuclear redistri-
bution of PML; however, IE2-86 alone does not disrupt ND10
(1). Coexpression of mdm2 with PML causes nuclear exclusion
of PML (62) and thus could block a potentially important
event in HCMV replication.
There is evidence to suggest that HCMV may alter the cell
cycle of infected cells to a state resembling late G1 to facilitate
viral replication (18, 63). In limited systems mdm2 stimulated
S-phase progression (20, 48) and thus functional mdm2 could
alter the balance toward cellular rather than viral proliferation.
The Sp1 transcription factor is stimulated in productive
HCMV infection (67). mdm2 binds Sp1 and blocks Sp1 tran-
scriptional activity (35) but can be reversed by Rb (35). A
virion protein, pp71, causes degradation of Rb and related
proteins (38). However, the accumulation of Rb during
HCMV infection (32) suggests that downregulation of mdm2
to facilitate Sp1 induction may not be a sustained viral repli-
cation strategy. We also note that the fact that an event occurs
during productive viral replication is not prima facie evidence
that the event is conducive to viral replication. Infrequently
they are not. For example, systematic gene deletions of the
HCMV genome revealed that removal of 4 out of 162 genes
resulted in enhanced viral fitness (21).
We have shown that mdm2 levels were decreased in HCMV-
infected cells due to accelerated degradation and that the viral
IE2-86 protein was likely responsible. The interactions be-
tween IE2-86 and mdm2 appeared to be specific and occurred
in the absence of other candidate adaptor molecules. HCMV
FIG. 10. Upper panel: putative LIM domain in IE2-86. Partial IE2-86
amino acid sequence from the Towne strain of HCMV. Residues sug-
gesting a double zinc finger (LIM) domain are underlined. Lower panel:
summary of the functions of IE2-86 mutants in this study. The altered
regions of the IE2-86 mutants employed in this study are presented with-
out epitope tags. Their corresponding effects upon the functions of mdm2
and p53 are indicated as positive () or negative ().
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infection results in cellular DNA damage (22) and the activa-
tion of signal transduction pathways that could be responsible
for p53 accumulation. For example, HCMV infection or
IE1-72 transfection induced ataxia telangiectasia-mutated ki-
nase-dependent p53 phosphorylation on residue Ser 15 (10).
However, others reported that in HCMV-infected cells or IE2-
86-expressing cells there was a direct correlation between the
relative amount of p53 and the relative amount of p53 phos-
phorylation (58). The data presented here suggest an alterna-
tive mechanism: p53 accumulation via IE2-86-dependent
mdm2 degradation (Fig. 11). This mechanism is likely to play
an important role in the context of HCMV infection because
siRNA-mediated knockdown of IE2-86 restored the accumu-
lation of mdm2 (Fig. 9).
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